

Shanghai Health Study - Conference call Friday, April 13 at 4 PM EDT
From: Howard Feldman [Feldman@api.org]
Sent: Friday, April 13, 2007 8:48 AM
To: BenzConsort-OC@listserve.api.org; BenzConsort-TC@listserve.api.org; BHRC
Communications Committee; myron.c.harrison@exxonmobil.com; Snyder, Phil J
SDIUS-DXX/9; Bob Greco; Brenda Hargett; Harry Ng
Subject: RE: Shanghai Health Study - Conference call Friday, April 13 at 4 PM
EDT

BHRC,

In advance of today's call, the draft follow-up List of Actions flowing from Wednesday's API Executive Committee call is listed below. (The final list may be slightly modified based on comments received from the Executive Committee.)

1. API will work with the SHS Oversight Committee chair to identify acceptance conditions

for an advance payment to Cinpathogen, Inc. (Cinpathogen) to maintain the operational

capabilities of the research program. Those conditions will include: 1) itemization of the

"how" and over what time period the \$800,000 advance payment is to be spent, 2)

identification of progress milestones to be achieved in the second quarter, 2007, and 3)

delineation of deliverables and milestones to be utilized in potential development of a

contract with Cinpathogen. These conditions will be forwarded ASAP to Dr. Richard Irons

for his acceptance.

2. Upon acceptance, and affirmation electronically to API, of those conditions by Dr. Irons,

API will then wire \$800,000 to Cinpathogen.

3. As part of API's ongoing due diligence, API and the Oversight Committee will examine 1)

Cinpathogen's incorporation papers, business plan and related financial statements and

banking relationships, and other items as needed to best assess the company's viability,

2) the Cinpathogen proposal and any subsequent revisions thereof, and 3) any underlying

agreements and contracts that Cinpathogen has established, or intends to establish, to

complete this study. API will ensure that any final proposal includes tying study payments to

metrics of progress towards study completion to occur no later than year end 2008.

4. The study will terminate at the end of 2008.

5. The API General Committee on Special Programs will be asked to play an active role in

overseeing the SHS program to ensure its timely completion by year end 2008.

6. API, working with the Oversight Committee, will provide the Executive Committee with a

risk/benefit analysis of contracting with Cinpathogen (a for-profit entity) to complete a

substantial portion of the remainder of this study, as opposed to a study under the

auspices of a not-for-profit organization.

7. API, working with the Oversight Committee, will provide the Executive Committee with a

risk/benefit analysis for the Benzene Health Research Consortium continuing as an API

Special Program with API continuing to serve as its program administrator, and a

companion risk/benefit analysis of the consortium acting apart from API as a separate

entity for the remainder of the program.

Howard Feldman

--

From: Russell White [mailto:whiter@api.org]
Sent: Thursday, April 12, 2007 9:16 AM
To: BenzConsort-OC@listserve.api.org; BenzConsort-TC@listserve.api.org; BHRC
Communications Committee; myron.c.harrison@exxonmobil.com;
phil.snyder@shell.com
Subject: Shanghai Health Study - Conference call Friday, April 13 at 4 PM EDT

SHELL-MCCLURG-066275

A conference call has been scheduled for Friday, April 13 at 4 PM EDT to discuss the Shanghai Health Study.

Draft Agenda

- 1) Establish quorum and notetaker - Patsy
- 2) Antitrust reminder - Mark
- 3) Update on API Executive Committee call - Howard
- 4) Update on call with Otto Wong - Jennifer
- 5) Update on Cinpathogen contract proposal - Russ
- 6) Other issues - All
- 7) Next meeting or call - Patsy

Conference call:

Toll Free Dial-In Number: (866) 443-0059
International Dial-In: (770) 765-9147

Enter this code at the prompt: 202 682 8344#

Operator-Assisted Service:

Toll-Free Dial-In Number: (800) 572-9844
International Dial-In Number: (706) 643-1733

Call Participant Functions

- *0 Operator assistance
- *6 Mute your own line

Russell White
Regulatory and Scientific Affairs
American Petroleum Institute
1220 L Street NW
Washington, DC 20005-4070

Tel: 202-682-8344
Fax: 202-682-8270